Close Menu

NEW YORK (GenomeWeb) – Cancer Genetics said today that New York State has approved the company's Focus::Myeloid next-generation sequencing-based panel for myeloid malignancies.

The 54-gene panel provides information that clinicians can use to diagnose, provide prognosis, determine treatment options, and provide risk stratification for patients with acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.